✦ LIBER ✦

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

✍ Scribed by Pozniak, Anton; Markowitz, Martin; Mills, Anthony; Stellbrink, Hans-Juergen; Antela, Antonio; Domingo, Pere; Girard, Pierre-Marie; Henry, Keith; Nguyen, Thai; Piontkowsky, David; Garner, Will; White, Kirsten; Guyer, Bill

Book ID: 124103711
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 274 KB
Volume: 14
Category: Article
ISSN: 1473-3099
DOI: 10.1016/S1473-3099(14)70796-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Simplification to coformulated elvitegra

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial

✍ Arribas, Jose R; Pialoux, Gilles; Gathe, Joseph; Di Perri, Giovanni; Reynes, Jac 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 260 KB